Cargando…

An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)

Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each o...

Descripción completa

Detalles Bibliográficos
Autores principales: Esmaili, Haydarali, Mostafidi, Elmira, Mehramuz, Bahareh, Ardalan, Mohammadreza, Mohajel-Shoja, Mohammadali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Diabetic Nephropathy Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790190/
https://www.ncbi.nlm.nih.gov/pubmed/27047804
http://dx.doi.org/10.15171/jnp.2016.02
_version_ 1782420957898473472
author Esmaili, Haydarali
Mostafidi, Elmira
Mehramuz, Bahareh
Ardalan, Mohammadreza
Mohajel-Shoja, Mohammadali
author_facet Esmaili, Haydarali
Mostafidi, Elmira
Mehramuz, Bahareh
Ardalan, Mohammadreza
Mohajel-Shoja, Mohammadali
author_sort Esmaili, Haydarali
collection PubMed
description Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each other and complicate the condition. Evidence Acquisition: Directory of Open Access Journals (DOAJ), EMBASE, Google Scholar, PubMed, EBSCO, and Web of Science with keywords relevant to; Hemophagocytic syndrome, macrophage activation syndrome, interferon-gamma and thrombotic microangiopathy, have been searched. Results: Viral infection, rheumatologic disease and malignancies are the main underlying causes for secondary HPS. calcineurin inhibitors and viral infections are also the main underlying causes of TMA in transplant recipients. In this review, we discussed a 39-year-old male who presented with pancytopenia and renal allograft dysfunction. With the diagnosis of HPS induced TMA his renal condition and pancytopenia improved after receiving intravenous immunoglobulin (IVIG) and plasmapheresis therapy. Conclusions: HPS is an increasingly recognized disorder in the realm of different medical specialties. Renal involvement complicates the clinical picture of the disease, and this condition even is more complex in renal transplant recipients. We should consider the possibility of HPS in any renal transplant recipient with pancytopenia and allograft dysfunction. The combination of HPS with TMA future increases the complexity of the situation.
format Online
Article
Text
id pubmed-4790190
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Society of Diabetic Nephropathy Prevention
record_format MEDLINE/PubMed
spelling pubmed-47901902016-04-04 An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome) Esmaili, Haydarali Mostafidi, Elmira Mehramuz, Bahareh Ardalan, Mohammadreza Mohajel-Shoja, Mohammadali J Nephropathol Review Context: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each other and complicate the condition. Evidence Acquisition: Directory of Open Access Journals (DOAJ), EMBASE, Google Scholar, PubMed, EBSCO, and Web of Science with keywords relevant to; Hemophagocytic syndrome, macrophage activation syndrome, interferon-gamma and thrombotic microangiopathy, have been searched. Results: Viral infection, rheumatologic disease and malignancies are the main underlying causes for secondary HPS. calcineurin inhibitors and viral infections are also the main underlying causes of TMA in transplant recipients. In this review, we discussed a 39-year-old male who presented with pancytopenia and renal allograft dysfunction. With the diagnosis of HPS induced TMA his renal condition and pancytopenia improved after receiving intravenous immunoglobulin (IVIG) and plasmapheresis therapy. Conclusions: HPS is an increasingly recognized disorder in the realm of different medical specialties. Renal involvement complicates the clinical picture of the disease, and this condition even is more complex in renal transplant recipients. We should consider the possibility of HPS in any renal transplant recipient with pancytopenia and allograft dysfunction. The combination of HPS with TMA future increases the complexity of the situation. Society of Diabetic Nephropathy Prevention 2016-01 2015-07-15 /pmc/articles/PMC4790190/ /pubmed/27047804 http://dx.doi.org/10.15171/jnp.2016.02 Text en © 2016 The Author(s) Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Esmaili, Haydarali
Mostafidi, Elmira
Mehramuz, Bahareh
Ardalan, Mohammadreza
Mohajel-Shoja, Mohammadali
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title_full An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title_fullStr An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title_full_unstemmed An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title_short An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
title_sort update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790190/
https://www.ncbi.nlm.nih.gov/pubmed/27047804
http://dx.doi.org/10.15171/jnp.2016.02
work_keys_str_mv AT esmailihaydarali anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mostafidielmira anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mehramuzbahareh anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT ardalanmohammadreza anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mohajelshojamohammadali anupdateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT esmailihaydarali updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mostafidielmira updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mehramuzbahareh updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT ardalanmohammadreza updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome
AT mohajelshojamohammadali updateonrenalinvolvementinhemophagocyticsyndromemacrophageactivationsyndrome